Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Heartflow, Inc. (Nasdaq: HTFL), a medical technology company that applies artificial intelligence to coronary computed tomography angiography (CTA) for non-invasive coronary artery disease detection and management. Investors can review the company’s periodic and current reports to understand its financial condition, risk factors, and key operational developments.
Heartflow’s Form 10-K annual reports and Form 10-Q quarterly reports describe its business as a commercial-stage provider of non-invasive CAD detection solutions built around the Heartflow One platform, including FFRCT Analysis and Plaque Analysis. These filings typically discuss revenue sources, geographic operations in regions such as the United States, the United Kingdom, Japan, and the rest of Europe, and the company’s status as an emerging growth company listed on the Nasdaq Global Select Market.
Form 8-K current reports offer more immediate updates on material events, such as financial results releases, participation in financing transactions, or changes to credit agreements. For example, Heartflow has used Form 8-K to furnish earnings press releases and to disclose the prepayment and termination of a prior credit agreement following its initial public offering.
Through this page, users can also locate proxy statements and executive compensation disclosures, as well as Form 4 insider transaction reports when applicable. Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight important risk disclosures, and clarify how Heartflow’s CAD-focused health information services and AI technologies are reflected in its regulatory reporting. Real-time updates from the SEC’s EDGAR system ensure that new HTFL filings, including 10-Ks, 10-Qs, 8-Ks, and ownership reports, are available promptly for detailed review.
HealthCor-related entities reported acquisitions of Heartflow, Inc. (HTFL) securities on 08/11/2025 recorded in a joint Form 4 filing. The filing shows HealthCor Partners Fund, L.P. acquired 1,248,939 common shares (as-converted from Series C preferred), HealthCor Partners Fund II, L.P. acquired 833,075 common shares (as-converted), and HCPCIV 1, LLC acquired 4,615,542 common shares (as-converted). Multiple preferred series and a convertible promissory note were reported as automatically converted into specified common share amounts immediately prior to Heartflow's IPO closing. Reporting signatures are dated 08/22/2025.
HealthCor-affiliated entities reported initial beneficial ownership in Heartflow, Inc. (HTFL). Multiple HealthCor funds and affiliates each hold various series of convertible preferred stock and a convertible promissory note that will convert into Heartflow common stock upon the closing of Heartflow's initial public offering. Conversion ratios after a 1-for-2.92 reverse split are disclosed for Series C, D, E, F and F-1 preferred stock and a conversion mechanism is disclosed for the promissory note (80% of IPO price, subject to a $2.0 billion valuation cap). HealthCor Partners Management, L.P. is the investment manager with voting and investment discretion and disclaims direct beneficial ownership except for pecuniary interests.
Bain Capital Life Sciences Investors, LLC and affiliated entities reported conversions of pre-IPO securities into Heartflow, Inc. common stock on 08/11/2025. The Issuer's Series F Preferred Stock converted on a 0.342466:1 basis into 12,014,234 common shares. A Subordinated Convertible Promissory Note with principal $6,595,648.51 converted into 433,924 common shares at a stated conversion price of $15.2. Following these transactions, the reporting group beneficially owned 12,448,158 common shares. The filings identify the reporting persons as directors and 10% owners and disclose an indirect ownership chain through several Bain Capital entities, with customary disclaimers about beneficial ownership.